Literature DB >> 11688463

Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.

T J Colgan1, J Murphy, D E Cole, S Narod, B Rosen.   

Abstract

Prophylactic oophorectomy (PO) is an option for women at increased risk for ovarian carcinoma. In this study the value of intensive pathologic examination of PO specimens and accompanying resected tissues in the identification of occult carcinoma and any association of occult carcinoma with BRCA germline mutation status were ascertained. Specimens from 60 consecutive PO patients, who were not suspected of having any ovarian tumor at the time of surgery, were subjected to standardized, complete pathologic examination in a prospective study over an 8-year period. Extra-ovarian tissues were examined as well, but they were not subject to the same standardized protocol. Any occult carcinoma of the ovaries or fallopian tubes was noted. The BRCA status and follow-up of patients were obtained, if available. Fifty-five of the 60 PO specimens did not show any evidence of malignancy. Of the 32 patients in this group followed for >1 year, all are alive and well. The remaining five patients, all BRCA1 mutation positive, showed occult carcinoma of the ovaries and/or in situ or invasive carcinoma of a fallopian tube. One of these five patients has died of abdominal carcinomatosis; four continue to be well, but follow-up is <4 years in all cases. Occult carcinoma is present in a small proportion of BRCA-positive or unknown PO patients and may be of prognostic significance. The entire ovaries and tubes from PO patients should be submitted for histologic examination to identify malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688463     DOI: 10.1097/00000478-200110000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  78 in total

1.  Costs of prophylactic resection.

Authors:  Terence J Colgan; Robert H Riddell; Aaron Pollett
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

2.  Recommendations for the reporting of fallopian tube neoplasms.

Authors:  Teri A Longacre; Esther Oliva; Robert A Soslow
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

3.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

4.  Preventing ovarian cancer by salpingectomy.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

5.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

6.  Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Authors:  Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

7.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

8.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

9.  Oncofertility in Canada: cryopreservation and alternative options for future parenthood.

Authors:  R Ronn; H E G Holzer
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 10.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.